Literature DB >> 14732329

Burden of hospitalization of patients with Candida and Aspergillus infections in Australia.

Monica Slavin1, John Fastenau, Isaya Sukarom, Panagiotis Mavros, Steven Crowley, William C Gerth.   

Abstract

OBJECTIVES: This study examined the burden of hospitalization of patients with Aspergillus and Candida infections in Australia from 1995 to 1999.
METHODS: Data were extracted from the National Hospital Morbidity Database. A hospitalization with an aspergillosis diagnosis was defined as any discharge with a diagnosis of aspergillosis. A hospitalization with a candidiasis diagnosis was defined as any discharge with a diagnosis of disseminated, invasive, or non-invasive candidiasis. Outcome measures included number of hospitalizations, length of stay (LOS), cost (AUS$), and mortality.
RESULTS: 4583 hospitalizations with an aspergillosis diagnosis and 57,758 hospitalizations with a candidiasis diagnosis were identified. These hospitalizations were associated with a total of 813,398 hospital days, AUS$563 million in cost, and 4967 in-hospital deaths during the study period. The mean LOS for a hospitalization with an aspergillosis diagnosis was 12 days, cost AUS$9,334, and was associated with 8% mortality. For disseminated, invasive, and non-invasive candidiasis, the respective mean LOS were 31, 17, and 12 days; costs were AUS$33,274, AUS$12,954, and AUS$7,694; and mortality was 26%, 9%, and 8%.
CONCLUSIONS: Hospitalizations with diagnoses for fungal infections were associated with lengthy hospital stays, high costs, and high mortality.

Entities:  

Mesh:

Year:  2004        PMID: 14732329     DOI: 10.1016/j.ijid.2003.05.001

Source DB:  PubMed          Journal:  Int J Infect Dis        ISSN: 1201-9712            Impact factor:   3.623


  13 in total

Review 1.  Multidrug resistance in fungi.

Authors:  Kailash Gulshan; W Scott Moye-Rowley
Journal:  Eukaryot Cell       Date:  2007-09-14

Review 2.  Candida identification: a journey from conventional to molecular methods in medical mycology.

Authors:  Mohammad Zubair Alam; Qamre Alam; Asif Jiman-Fatani; Mohammad Amjad Kamal; Adel M Abuzenadah; Adeel G Chaudhary; Mohammad Akram; Absarul Haque
Journal:  World J Microbiol Biotechnol       Date:  2014-01-01       Impact factor: 3.312

3.  Economic evaluation of micafungin versus liposomal amphotericin B (LAmB) for treating patients with candidaemia and invasive candidiasis (IC) in Turkey.

Authors:  Chin Fen Neoh; Esin Senol; Ates Kara; Ener Cagri Dinleyici; Stuart J Turner; David C M Kong
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-06-30       Impact factor: 3.267

4.  Attributable hospital cost and antifungal treatment of invasive fungal diseases in high-risk hematology patients: an economic modeling approach.

Authors:  Michelle R Ananda-Rajah; Allen Cheng; C Orla Morrissey; Tim Spelman; Michael Dooley; A Munro Neville; Monica Slavin
Journal:  Antimicrob Agents Chemother       Date:  2011-02-28       Impact factor: 5.191

5.  Diagnosis and inflammatory response of patients with candiduria.

Authors:  S Helbig; J M Achkar; N Jain; X Wang; P Gialanella; M Levi; B C Fries
Journal:  Mycoses       Date:  2012-05-10       Impact factor: 4.377

6.  Cost-effectiveness of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infections among high-risk neutropenic patients in Spain.

Authors:  Santiago Grau; Rafael de la Cámara; Francisco J Sabater; Isidro Jarque; Enric Carreras; Miguel A Casado; Miguel A Sanz
Journal:  BMC Infect Dis       Date:  2012-04-03       Impact factor: 3.090

7.  Fluconazole for empiric antifungal therapy in cancer patients with fever and neutropenia.

Authors:  Donghui T Yu; Diane L Seger; Josh F Peterson; Ritesh N Kumar; David W Bates
Journal:  BMC Infect Dis       Date:  2006-12-05       Impact factor: 3.090

8.  Antifungal chemical compounds identified using a C. elegans pathogenicity assay.

Authors:  Julia Breger; Beth Burgwyn Fuchs; George Aperis; Terence I Moy; Frederick M Ausubel; Eleftherios Mylonakis
Journal:  PLoS Pathog       Date:  2007-02       Impact factor: 6.823

Review 9.  Candida Bloodstream Infections: Changes in Epidemiology and Increase in Drug Resistance.

Authors:  Fleischer Cn Kotey; Nicholas Tkd Dayie; Patience B Tetteh-Uarcoo; Eric S Donkor
Journal:  Infect Dis (Auckl)       Date:  2021-06-24

10.  Galactomannan antigen assay from bronchoalveolar lavage fluid in diagnosis of invasive pulmonary aspergillosis in intensive care units patients.

Authors:  Farzin Khorvash; Mohsen Meidani; Leila Babaei; Saeed Abbasi; Behrooz Ataei; Majid Yaran
Journal:  Adv Biomed Res       Date:  2014-01-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.